Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETECT III: Lapatinib in HER2-negative MBC with HER2-positive CTCs
NCT01619111Phase 3Completed
- Sponsor
- Prof. Wolfgang Janni
- Start
- Feb 2012
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lapatinib in breast cancer, sponsored by Prof. Wolfgang Janni. Started Feb 2012; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01619111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01619111.